News

Alizé Pharma 3 Rebrands as Amolyt Pharma, Plans AZP-3601 Trial

Alizé Pharma 3 is rebranding as Amolyt Pharma and plans to start clinical testing of a potential hypoparathyroidism treatment known as AZP-3601 later this year. “Our new name, Amolyt Pharma, is derived from ammolite, a rare gemstone originating from living organisms,” Thierry Abribat, PhD, the company’s founder and…

Inadequate Medical Care Still a Major Struggle in US, Survey Finds

People with hypoparathyroidism living in the U.S. still struggle to receive proper medical care, particularly during emergency room visits, according to findings of a survey conducted by the HypoPARAthyroidism Association (HPA). The results of the HPA’s “Voices of Hypopara” survey were released in support of World Hypoparathyroidism…

Unity and EU-wide Efforts Focus of Online Rare Disease Meeting

Eurordis, a Paris-based coalition of national rare disease associations across Europe, hosted its first all-virtual conference, bringing some 1,500 delegates from 57 countries together online during the COVID-19 pandemic. The 10th European Conference on Rare Diseases & Orphan Products (ECRD2020) — which was set for May 14–15 in…